Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVRNASDAQ:BLUENASDAQ:CMPXNASDAQ:DBVT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$2.91+4.3%$6.08$7.96▼$24.15$14.68M0.6316,394 shs39,619 shsBLUEbluebird bio$4.78-4.1%$4.42$3.20▼$28.60$46.77M0.27425,833 shs324,312 shsCMPXCompass Therapeutics$2.15+2.1%$1.90$0.77▼$4.08$296.62M1.4921,167 shs131,499 shsDBVTDBV Technologies$8.78-6.1%$8.27$2.20▼$12.78$239.53M-0.66190,050 shs30,941 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir+4.30%-12.61%-56.57%-69.40%-83.24%BLUEbluebird bio-0.40%+0.20%+18.85%+31.05%-73.51%CMPXCompass Therapeutics-0.47%+1.94%+10.53%-28.08%+37.25%DBVTDBV Technologies+0.65%+0.21%+1.96%+122.62%+56.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALVRAlloVirN/AN/AN/AN/AN/AN/AN/AN/ABLUEbluebird bio3.0737 of 5 stars3.15.00.00.02.31.71.3CMPXCompass Therapeutics4.0204 of 5 stars4.63.00.00.03.45.00.0DBVTDBV Technologies3.1775 of 5 stars3.55.00.00.02.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/ABLUEbluebird bio 2.25Hold$44.60834.03% UpsideCMPXCompass Therapeutics 3.11Buy$13.13511.89% UpsideDBVTDBV Technologies 2.50Moderate Buy$14.7568.01% UpsideCurrent Analyst Ratings BreakdownLatest BLUE, CMPX, DBVT, and ALVR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025DBVTDBV TechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSell$7.255/27/2025DBVTDBV TechnologiesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/27/2025DBVTDBV TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$15.00 ➝ $21.005/9/2025CMPXCompass TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $10.005/5/2025DBVTDBV TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $16.005/1/2025DBVTDBV TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $15.004/28/2025CMPXCompass TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/22/2025CMPXCompass TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/21/2025CMPXCompass TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.004/21/2025CMPXCompass TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/4/2025CMPXCompass TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $24.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/ABLUEbluebird bio$103.95M0.45N/AN/A$35.59 per share0.13CMPXCompass Therapeutics$850K348.96N/AN/A$1.17 per share1.83DBVTDBV Technologies$15.73M15.29N/AN/A$7.27 per share1.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%8/7/2025 (Estimated)BLUEbluebird bio-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%N/ACMPXCompass Therapeutics-$42.49M-$0.41N/AN/AN/AN/A-32.37%-30.67%8/11/2025 (Estimated)DBVTDBV Technologies-$72.73M-$4.92N/AN/AN/A-815.73%-106.07%-76.17%7/29/2025 (Estimated)Latest BLUE, CMPX, DBVT, and ALVR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CMPXCompass Therapeutics-$0.12-$0.12N/A-$0.12N/AN/A4/11/2025Q4 2024DBVTDBV TechnologiesN/A-$1.10N/A-$1.10N/A$0.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/ABLUEbluebird bioN/AN/AN/AN/AN/ACMPXCompass TherapeuticsN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78BLUEbluebird bio0.370.510.33CMPXCompass TherapeuticsN/A31.8431.84DBVTDBV TechnologiesN/A2.222.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%BLUEbluebird bio87.43%CMPXCompass Therapeutics68.43%DBVTDBV Technologies71.74%Insider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%BLUEbluebird bio1.40%CMPXCompass Therapeutics29.80%DBVTDBV Technologies1.44%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionOptionableBLUEbluebird bio5209.79 million9.59 millionOptionableCMPXCompass Therapeutics20138.28 million98.38 millionNot OptionableDBVTDBV Technologies8027.39 million20.18 millionOptionableBLUE, CMPX, DBVT, and ALVR HeadlinesRecent News About These CompaniesJMP Securities Forecasts Strong Price Appreciation for DBV Technologies (NASDAQ:DBVT) StockMay 29 at 1:15 AM | americanbankingnews.comDBV Technologies (NASDAQ:DBVT) Price Target Raised to $21.00May 28 at 8:15 AM | marketbeat.comPoint72 Asset Management L.P. Has $885,000 Holdings in DBV Technologies S.A. (NASDAQ:DBVT)May 25, 2025 | marketbeat.comAre Medical Stocks Lagging DBV Technologies (DBVT) This Year?May 21, 2025 | zacks.comAre You Looking for a Top Momentum Pick? Why DBV Technologies S.A. (DBVT) is a Great ChoiceMay 16, 2025 | msn.comAre You Looking for a Top Momentum Pick? Why DBV Technologies S.A.May 16, 2025 | zacks.comDBV Technologies (DBVT) Is a Great Choice for 'Trend' Investors, Here's WhyMay 16, 2025 | zacks.comCombined General Meeting of June 11, 2025May 15, 2025 | globenewswire.comDBV Technologies: A Great Time To SellMay 14, 2025 | seekingalpha.comDBV Technologies (NASDAQ:DBVT) Rating Increased to Hold at StockNews.comMay 11, 2025 | marketbeat.comHC Wainwright Has Bullish Estimate for DBVT FY2025 EarningsMay 10, 2025 | marketbeat.comHC Wainwright Has Positive Outlook of DBVT FY2026 EarningsMay 9, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for DBVT Q2 Earnings?May 8, 2025 | marketbeat.comDBV Technologies (NASDAQ:DBVT) Given New $16.00 Price Target at HC WainwrightMay 7, 2025 | marketbeat.comBaker BROS. Advisors LP Has $4.52 Million Holdings in DBV Technologies S.A. (NASDAQ:DBVT)May 6, 2025 | marketbeat.comDBV Technologies to Participate in the Citizens JMP Life Sciences ConferenceMay 5, 2025 | globenewswire.comDBV Technologies (NASDAQ:DBVT) Share Price Passes Above 50-Day Moving Average - Should You Sell?May 4, 2025 | marketbeat.com50,000 Shares in DBV Technologies S.A. (NASDAQ:DBVT) Acquired by Boxer Capital Management LLCMay 4, 2025 | marketbeat.comDBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.comMay 3, 2025 | marketbeat.comDBV Technologies S.A.: DBV Technologies Reports First Quarter 2025 Financial ResultsMay 1, 2025 | finanznachrichten.deDBV Technologies Reports First Quarter 2025 Financial ResultsApril 30, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long3 Alternative Asset Managers Are Raising Dividends by 5% to 25%By Leo Miller | May 13, 2025View 3 Alternative Asset Managers Are Raising Dividends by 5% to 25%Don’t Take Dick’s Sporting Goods Seriously? Big MistakeBy Thomas Hughes | May 29, 2025View Don’t Take Dick’s Sporting Goods Seriously? Big MistakeBLUE, CMPX, DBVT, and ALVR Company DescriptionsAlloVir NASDAQ:ALVR$2.91 +0.12 (+4.30%) As of 05/27/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.bluebird bio NASDAQ:BLUE$4.78 -0.21 (-4.12%) As of 11:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.Compass Therapeutics NASDAQ:CMPX$2.14 +0.05 (+2.14%) As of 11:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.DBV Technologies NASDAQ:DBVT$8.78 -0.57 (-6.11%) As of 11:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? CrowdStrike Stock Slips: Analyst Downgrades Before Earnings AutoZone Stock to Cross $4400 This Year: This Is Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
